Low-dose enteric-coated aspirin: A practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase

Joseph A. Jakubowski, Meir J. Stampfer, Raymond Vaillancourt, Douglas Orrick Faigel, Daniel Deykin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Using a granular enteric-coated aspirin (ECA) preparation, we achieved continuous release of low-dose aspirin and associated inhibition of platelet reactivity. The lowest once-daily dose that produced >90% inhibition of serum thromboxane (TX) A2 after 7 days was 80 mg. The time course of inhibition after the first dose indicated a gradual release of aspirin over a period of 8 hours. We subsequently fractionated this 80 mg dose into three times daily doses of 27 mg that were administered to nine healthy men for 7 days. This regimen resulted in 96% inhibition of serum TXA2 generation (P < 0.001), inhibition of in vitro platelet aggregation (P < 0.05), prolongation of the bleeding time by 75% (P < 0.01), and a threefold increase in inhibition of platelet aggregation by prostacyclin (P < 0.01) compared with pre-ECA values. In contrast to our previous study using daily 80 mg doses of ECA, after the 27 mg three times daily regimen we found a significant increase in circulating platelet cyclooxygenase activity 24 hours after the final dose (P < 0.05). This Immediate recovery indicates active megakaryocyte cyclooxygenase and suggests that acetylation of platelet cyclooxygenase was restricted to the presystemic circulation. We conclude that longterm dosing with 27 mg ECA three times daily results in profound inhibition of platelet TXA2 production, and diminished in vitro and in vivo platelet reactivity. This regimen provides a practical approach to achieving continuous release of low-dose aspirin and possible presystemic acetylation of platelet cyclooxygenase.

Original languageEnglish (US)
Pages (from-to)616-621
Number of pages6
JournalThe Journal of Laboratory and Clinical Medicine
Volume108
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Acetylation
Prostaglandin-Endoperoxide Synthases
Platelets
Aspirin
Blood Platelets
Platelet Aggregation
Agglomeration
Thromboxane A2
Bleeding Time
Megakaryocytes
Epoprostenol
Serum
Recovery

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Low-dose enteric-coated aspirin : A practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. / Jakubowski, Joseph A.; Stampfer, Meir J.; Vaillancourt, Raymond; Faigel, Douglas Orrick; Deykin, Daniel.

In: The Journal of Laboratory and Clinical Medicine, Vol. 108, No. 6, 1986, p. 616-621.

Research output: Contribution to journalArticle

@article{37511a98e2d84abdba45fc6ce0e7bda2,
title = "Low-dose enteric-coated aspirin: A practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase",
abstract = "Using a granular enteric-coated aspirin (ECA) preparation, we achieved continuous release of low-dose aspirin and associated inhibition of platelet reactivity. The lowest once-daily dose that produced >90{\%} inhibition of serum thromboxane (TX) A2 after 7 days was 80 mg. The time course of inhibition after the first dose indicated a gradual release of aspirin over a period of 8 hours. We subsequently fractionated this 80 mg dose into three times daily doses of 27 mg that were administered to nine healthy men for 7 days. This regimen resulted in 96{\%} inhibition of serum TXA2 generation (P < 0.001), inhibition of in vitro platelet aggregation (P < 0.05), prolongation of the bleeding time by 75{\%} (P < 0.01), and a threefold increase in inhibition of platelet aggregation by prostacyclin (P < 0.01) compared with pre-ECA values. In contrast to our previous study using daily 80 mg doses of ECA, after the 27 mg three times daily regimen we found a significant increase in circulating platelet cyclooxygenase activity 24 hours after the final dose (P < 0.05). This Immediate recovery indicates active megakaryocyte cyclooxygenase and suggests that acetylation of platelet cyclooxygenase was restricted to the presystemic circulation. We conclude that longterm dosing with 27 mg ECA three times daily results in profound inhibition of platelet TXA2 production, and diminished in vitro and in vivo platelet reactivity. This regimen provides a practical approach to achieving continuous release of low-dose aspirin and possible presystemic acetylation of platelet cyclooxygenase.",
author = "Jakubowski, {Joseph A.} and Stampfer, {Meir J.} and Raymond Vaillancourt and Faigel, {Douglas Orrick} and Daniel Deykin",
year = "1986",
language = "English (US)",
volume = "108",
pages = "616--621",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Low-dose enteric-coated aspirin

T2 - A practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase

AU - Jakubowski, Joseph A.

AU - Stampfer, Meir J.

AU - Vaillancourt, Raymond

AU - Faigel, Douglas Orrick

AU - Deykin, Daniel

PY - 1986

Y1 - 1986

N2 - Using a granular enteric-coated aspirin (ECA) preparation, we achieved continuous release of low-dose aspirin and associated inhibition of platelet reactivity. The lowest once-daily dose that produced >90% inhibition of serum thromboxane (TX) A2 after 7 days was 80 mg. The time course of inhibition after the first dose indicated a gradual release of aspirin over a period of 8 hours. We subsequently fractionated this 80 mg dose into three times daily doses of 27 mg that were administered to nine healthy men for 7 days. This regimen resulted in 96% inhibition of serum TXA2 generation (P < 0.001), inhibition of in vitro platelet aggregation (P < 0.05), prolongation of the bleeding time by 75% (P < 0.01), and a threefold increase in inhibition of platelet aggregation by prostacyclin (P < 0.01) compared with pre-ECA values. In contrast to our previous study using daily 80 mg doses of ECA, after the 27 mg three times daily regimen we found a significant increase in circulating platelet cyclooxygenase activity 24 hours after the final dose (P < 0.05). This Immediate recovery indicates active megakaryocyte cyclooxygenase and suggests that acetylation of platelet cyclooxygenase was restricted to the presystemic circulation. We conclude that longterm dosing with 27 mg ECA three times daily results in profound inhibition of platelet TXA2 production, and diminished in vitro and in vivo platelet reactivity. This regimen provides a practical approach to achieving continuous release of low-dose aspirin and possible presystemic acetylation of platelet cyclooxygenase.

AB - Using a granular enteric-coated aspirin (ECA) preparation, we achieved continuous release of low-dose aspirin and associated inhibition of platelet reactivity. The lowest once-daily dose that produced >90% inhibition of serum thromboxane (TX) A2 after 7 days was 80 mg. The time course of inhibition after the first dose indicated a gradual release of aspirin over a period of 8 hours. We subsequently fractionated this 80 mg dose into three times daily doses of 27 mg that were administered to nine healthy men for 7 days. This regimen resulted in 96% inhibition of serum TXA2 generation (P < 0.001), inhibition of in vitro platelet aggregation (P < 0.05), prolongation of the bleeding time by 75% (P < 0.01), and a threefold increase in inhibition of platelet aggregation by prostacyclin (P < 0.01) compared with pre-ECA values. In contrast to our previous study using daily 80 mg doses of ECA, after the 27 mg three times daily regimen we found a significant increase in circulating platelet cyclooxygenase activity 24 hours after the final dose (P < 0.05). This Immediate recovery indicates active megakaryocyte cyclooxygenase and suggests that acetylation of platelet cyclooxygenase was restricted to the presystemic circulation. We conclude that longterm dosing with 27 mg ECA three times daily results in profound inhibition of platelet TXA2 production, and diminished in vitro and in vivo platelet reactivity. This regimen provides a practical approach to achieving continuous release of low-dose aspirin and possible presystemic acetylation of platelet cyclooxygenase.

UR - http://www.scopus.com/inward/record.url?scp=0022979687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022979687&partnerID=8YFLogxK

M3 - Article

C2 - 3097223

AN - SCOPUS:0022979687

VL - 108

SP - 616

EP - 621

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 6

ER -